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Spinal muscular atrophy (SMA) is a motor neuron disease (MND) in humans and diverse
animal species: canid, felid, and bovid. To date, bovine SMA has been reported in
Brown Swiss, Holstein, Friesian, and Red Danish breed; it has been associated with a
genetic mutation of the FVT1 gene, also known as 3-ketodihydrosphingosine reductase
(KDSR). The aim of the present case series was to describe clinical presentation,
pathological findings, and genetic analysis of five Blond d’Aquitaine calves diagnosed
with SMA and to determine whether the mutation was associated with the disease.
Five Blonde d’Aquitaine calves (three females and two males) from the same cow-calf
operation farm were presented between June 2018 and February 2019 because unable
to stand or walk unassisted since birth. Neurological examination aroused suspicion
of a diffuse lesion affecting the peripheral nervous system in all calves. Findings
from electromyographic investigations and muscle and nerve biopsies were consistent
with a non-regenerative, chronic, active axonal neuropathy and marked neurogenic
muscular atrophy and assumed to be associated with a neurodegenerative process.
Histopathological examination of tissue samples from two animals revealed neuronal loss
and several degenerated, shrunken, and hypereosinophilic neurons at the level of the
ventral horn of the cervico-thoracic and the lumbo-sacral intumescence, diffuse loss of
myelinated axons at the level of the ventral funiculi of all segments of the spinal cord, and
moderate diffuse astrocytic reaction. These findings confirmed the diagnosis of SMA. No
mutation of the FVT1 genewas found on genetic analysis. Further study into the causative
gene mutation of SMA in Blonde D’Aquitaine calves is under way. Identification of a novel
genetic mutation could improve our understanding of the disease in human medicine.
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BACKGROUND
SMA is a MND in humans and diverse animal species: canid, felid and bovid (1–6). These central
nervous system disorders usually affect somatic lower motor neurons of the anterior/ventral horns
of the spinal cord and surrounding myelin; other regions of the central nervous system, including
the brainstem and the motor cortex, can be affected as well. Clinically, MNDs are characterized by
neurogenic muscle atrophy, paresis, and hyporeflexia usually without sensory involvement.
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The etiology of these syndromes in humanmedicine is broadly
classified as genetic, though sporadic and immune-mediated
cases can also occur (7). To date, bovine SMA has been reported
in Brown Swiss, Holstein, Friesian, and Red Danish breed; it
has been associated with a genetic mutation of the FVT1 gene,
also known as 3-ketodihydrosphingosine reductase (KDSR) (8).
KDSR encodes one of several enzymes of the glycosphingolipid
pathways that catalyze the second step in the biosynthesis of the
sphingosine and ceramide central precursors of this pathway. A
transition from G to A at the first nucleotide of codon 36 of exon
6, determining the substitution of Ala175 with Thr175, is thought
to be the causative mutation of SMA or perhaps a marker in
perfect linkage disequilibrium with the causative mutation (8).
The aim of the present case series was to describe the clinical
presentation, pathological findings, and genetic analysis of five
Blond d’Aquitaine calves diagnosed with SMA and to determine
whether the mutation was also associated with the disease.
CASE DESCRIPTION
Five Blonde d’Aquitaine calves (three females and two males)
from the same cow-calf operation farm were presented to the
Mobile Clinic Service of the Veterinary Teaching Hospital,
Department of Veterinary Science of Turin (Italy) between June
2018 and February 2019 because they were unable to stand or
walk unassisted since birth. The median age at presentation was
10 days (range 7–14); all calves were born by natural service from
the same bull. Clinical examination was normal in three calves;
pressure sores were noted in two; generalized muscle atrophy
was also appreciable. Neurological examination performed by
a board-certified neurologist (A.D.A.) was comparable for all
patients. The calves were alert and responsive. Gait evaluation
revealed a non-ambulatory flaccid tetraparesis with diffuse
hyporeflexia in all four limbs. Cranial nerve examination
revealed no abnormalities and no pain upon palpation of the
vertebral coloumn and muscles. Findings from the neurological
examination aroused suspicion of a diffuse lesion affecting
the peripheral nervous system. Based on animals age, history
and clinical presentation, a congenital or degenerative disease
was suspected. Differential diagnoses included a metabolic/toxic
disease or an infectious/inflammatory process.
Hematology and serum biochemistry were unremarkable,
except for neutrophilic leukocytosis in two animals (8.10 × 103
cells/µl and 7.55× 103 cells/µl, respectively; reference range 1.1–
3.6 × 103 cells/µl) attributed to inflammation of the pressure
sores noted at clinical examination. Cerebrospinal fluid collected
from the lumbar cistern was normal.
Electromyography performed in one animal revealed
spontaneous muscular activity characterized mainly by
fibrillation potentials and positive sharp waves in the
appendicular and the paravertebral muscles: supraspinatus,
infraspinatus, biceps, triceps, and extensor carpis radialis
muscles of the thoracic limbs; quadriceps, gluteus, tibialis
cranialis muscles of the pelvic limbs, and epaxial muscles.
Abbreviations: SMA, Spinal muscular atrophy; KDSR, 3-ketodihydrosphingosine
reductase; MND, motor neuron disease.
FIGURE 1 | Transverse section of tibialis cranialis. Diffuse neurogenic
muscular atrophy with atrophic angular fibers and hypetrophic fibers
(asterisks). Endomysial fibrosis is also evident (arrows). HE ×400.
Electromyography was performed by means of Myto
electromyography system (EB Neuro, Firenze, Italy) and
coaxial needle electrodes for electromyography (Bionen s.a.s,
Firenze, Italy).
Muscle (triceps brachialis and tibialis cranialis) and nerve
(common peroneal) biopsy from the same calf were performed
on the side contralateral to electromyography. Biopsy samples
were obtained by an open procedure. Transverse muscle
cryosections (10-µm thick) were stained with hematoxylin-
eosin, modified Gomori trichrome, Periodic-acid Schiff, Oil
Red O, ATPase pH 9.8, ATPase pH 4.3, esterase, nicotinamide
adenine dinucleotide, succinate dehydrogenase, and cytochrome
oxidase. Nerve biopsy was fixed in 2.5% glutaraldehyde in
0.1M cacodylate buffer at 4 ◦C, post fixed in OsO4, and
embedded in Epon Araldite. Transverse semi-thin (1µm)
sections were stained with methylene blue and observed at
light microscope. Histopathological evaluation of the muscle
biopsies revealed marked reduction in myofiber diameter,
with grouped angular and round-shaped atrophic fibers,
associated with multifocal hypertrophic myofibers. Terminal
stage muscle atrophy with perimysial and endomysial fibrosis
and pseudo-multiplication of nuclei was noted (Figure 1). No
abnormalities in myofiber distribution and oxidative pattern or
lipid or glycogen sarcoplasmatic accumulation were observed.
Intramuscular nervous fibers displayed loss of myelinized fibers
with multifocal axonal degeneration. Examination of peripheral
nerve samples revealed patchy loss of large and medium size
myelinized fibers, with diffuse axonal degeneration and absence
of regenerating fibers. Moderate endoneurial fibrosis was also
noted (Figure 2).
These findings were consistent with non-regenerative,
chronic, active axonal neuropathy and marked neurogenic
muscular atrophy assumed to be consistent with a
neurodegenerative process. SMA was suspected given the
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FIGURE 2 | Transverse section of the peroneal nerve. Patchy loss of large and
medium size myelinated fibers (arrows). Methylene blue ×500.
young age of the animals. In light of the poor prognosis of SMA
and for animal welfare reasons, all five calves were humanely
euthanized and post-mortem examination was performed
in two. No macroscopic changes were found, except for the
pressure sores noticed in two animals upon clinical examination.
Representative samples of brain and spinal cord tissues were
fixed in 10% formalin solution. Transverse sections were
routinely processed for histology and 4-µm sections were
stained with hematoxylin-eosin and Luxol fast blue. Selected
sections were stained immunohistochemically with polyclonal
rabbit antibody against glial fibrillary acidic protein (GFAP
1:1000; Dako, Z0334, Carpinteria, CA, USA) and monoclonal
mouse antibody against neuron-specific enolase (NSE 1:100;
Dako M0873). Histopathological examination revealed neuronal
loss and several degenerated, shrunken hypereosinophilic
neurons at the level of the ventral horn of the cervico-thoracic
and the lumbo-sacral intumescence. Immunoreactivity with
anti- neuron-specific enolase antibodies was not expressed by
degenerated neurons (Figure 3). Diffuse loss of myelinated axons
was observed at the level of the ventral funiculi of all segments
of the spinal cord (Figure 4) and immunohistochemistry with
glial fibrillary acidic protein revealed moderate diffuse astrocytic
reaction. No remarkable changes were observed in the brain.
The histopathological findings in the tissue samples from
muscle, peripheral nerve, and spinal cord were consistent with a
diagnosis of SMA.
Genetic investigation was performed based on observations
from a previous study (8). Genomic DNA was obtained from
blood samples from the calves and the dams and the bull.
Extraction was performed using the NucleoSpin R© Tissue kit
(Macherey-Nagel, Düren, Germany) and a region of 183 bp
FIGURE 3 | Ventral horn of the cervico-thoracic spinal cord. Degenerated
shrunken motor neurons do not express NSE (black arrows), whereas
morphologically normal neurons are immunolabelled (red arrows). IHC for NSE,
×400.
FIGURE 4 | Transverse section of the spinal cord at the level of ventral funiculi.
Marked loss of myelinated axons is associated with hypertrophic astrocytes
(arrows). LFB-HE, ×320.
was amplified with the primers described in literature (8)
using the HotStar Taq DNA Polymerase (Qiagen, Hilden,
Germany). The PCR fragments were then sequenced by the
LightRun Tube Sanger sequencing service of Eurofins genomics
(Ebersberg, Germany) and visualized, aligned, and edited
using BioEdit (Hall TA (1999) BioEdit: a user-friendly bio-
logical sequence alignment editor and analysis program for
Windows 95/98/NT. Nucl Acids Symp Ser 41:95–98). Genetic
investigations did not reveal mutations affecting the FVT1
gene in any of the animals tested. To exclude other possible
mutations in the same exon, a 336 bp fragment corresponding
to the entire exon 6 of KDSR was also amplified using
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the primers Fvt_ex6_f and r (CCCTGGGCTGAAAGGAATCA
and TGGGGCAGGGTACCTGAG, respectively), sequenced, and
analyzed as described above. No differences in any of the samples
were found, however.
DISCUSSION
To our knowledge, this is the first clinical, anatomopathological,
and genetic description of SMA in Blonde D’Aquitaine calves.
The first consistent description of SMA in cattle was reported
in 19 Brown Swiss calves in 1989. Clinical signs included
initial pelvic limb weakness at 3–4 weeks of age progressing
to tetraparesis and recumbency associated with severe muscle
atrophy. On autopsy, the main pathological findings were
motor neuron degeneration and loss in the ventral horns
of the spinal cord, with accumulation of neurofilaments and
mitochondria in the affected cells, and severe neurogenic atrophy
(3). A few years later, Troyer and colleagues published a
description of the clinical and neuropathological aspects of
SMA in 53 calves of the same breed (9). A similar clinical
presentation was reported in Braunvieh calves and in cross
calves of the two breeds (5, 6). In 1994, SMA was described
in Red Danish calves. Based on histopathology of spinal cord
and muscle tissue samples from 162 Red Danish calves with
suspected SMA, 82 were diagnosed with the disease. Age ranged
widely between those recumbent since birth and 21-week-
olds. Lesions were consistent with neuronal degeneration and
denervation muscular atrophy. A familial pattern, traced back
to American Brown Swiss Bulls, was identified at the time of
the study (10). In 1997, Pumarola and colleagues described
SMA in five Holstein-Friesian calves diagnosed on post-mortem
examination. The initial clinical signs of weakness noted at
the age of 15 days rapidly progressed to tetraparesis in 2
weeks. Electromyography was consistent with denervation and
neuropathological examination disclosed degeneration and loss
of motor neurons in the spinal cord (mainly in the ventral horn
of the cervico-thoracic and the lumbo-sacral intumescence),
presence of ghost cells, moderate astrocytosis, and accumulation
of phosphorylated neurofilaments.
The primary pathogenic processes underlying MND are
believed to be multifactorial, but the mechanism underlying
selective motor neuron death remains unknown. Numerous
pathogenic mechanisms contributing to motor neuron injury
and cell death in MND (and neurodegenerative diseases in
general) have been suggested: genetic factors, oxidative stress,
excitotoxicity, protein aggregation, mitochondrial dysfunction,
impairment of axonal transport, dysfunctional signaling
pathways and inflammatory cascades of non-neuronal cells
(11, 12).
Few veterinary studies to date have focused on the
pathogenesis of MND. The cause of motor neuron death is not
attributable to neurofilament accumulation alone. Synaptophysin
is a synaptic vescicle-associated glycoprotein expressed by
motor neurons. Immunohistochemical analysis of synaptophysin
expression on affected Holstein Friesian calves had been
performed in order to investigate whether the lower motor
neuron degeneration was a result of loss of afferent contacts. The
study revealed decreased expression of synaptophysin on affected
neurons, suggesting progressive loss of pre-synaptic terminals
because of abnormal signaling of target motor neurons rather
than primary loss of afferents, and no evidence of apoptotic
signals or caspase 1 and 3 activation, which are believed to have a
pivotal role in mediating cell death (4, 13). Furthermore, diffuse
astrogliosis associated with neuronal degeneration, as seen in
the present cases, is a well-described feature of MND in human
medicine (12).
Historically, several types of SMA in human medicine have
been differentiated according to age at onset and clinical course
(SMA I–IV). The first two have their onset in infancy and affected
patients never achieve the ability to sit unassisted (Type I, also
referred as Werding-Horrman disease) or walk independently
(Type II—Dubowitz disease). In SMA type III (also known as
Kugerberg-Welander disease), clinical signs become apparent
around 1 year of age, with progressive proximal weakness of
the legs in particular. SMA type IV, which accounts for <5% of
SMA cases, has its onset in adulthood, progresses slowly, and
is relatively benign (14, 15). Another type of SMA has been
defined as SMA type 0 because of its prenatal onset. Neonates
have a history of decreased fetal movements and present with
severe weakness, hypotonia, areflexia, and facial diplegia. Cardiac
defects and joint contractures are concurrently reported; life
expectancy is severely shortened due to respiratory failure (15).
Although involvement of brain structures is poorly documented
in patients with SMA, neuroimaging of the cortical gray matter
revealed supratentorial atrophy in three patients with SMA type
0, whereas the thalamus, basal ganglia, and cerebellum appeared
normal and the white matter displayed a normal myelination
pattern (16).
Based on the medical history of the calves in this series
(recumbency since birth), a diagnosis of SMA type 0 appears
plausible, though the lack of respiratory muscle involvement and
brain lesions tends to make a diagnosis of SMA type I more likely,
as suggested for other bovine breeds.
Most (95%) cases of SMA in human medicine are associated
withmutations in the SMN1 exon 7 gene located on chromosome
5q13, with an autosomal recessive mode of inheritance. The
SMN1 protein product is ubiquitous in all cells and important
in the formation of spliceosomes involved in the processing of
pre-mRNA into mRNA (17); however, it is uncertain why motor
neurons are particularly vulnerable for this defect (18).
Taking advantage of the remarkable similarities between
human and bovine SMA, genetic investigations have been carried
out on Braunvieh breed. In 2003, Medugorac and colleagues
initially hypothesized that the apoptosis-inhibiting protein
BCL2, located on chromosome 24, was the most promising
positional candidate gene (19). Fine-mapping of the bovine
SMA locus suggested other positional candidates, including its
immediate neighbor FVT1, which encodes KDSR, involved in
glycosphingolipid metabolism, and the VPA4B gene, involved
in other neurodegenerative diseases (20). In 2007, definitive
mapping of the functional mutation causing SMA in Braunvieh
to the FVT1 gene demonstrated that, despite the clinical and
pathological similarities, bovine and human SMA were caused
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by mutations in completely different genes (8). No mutation of
the FVT1 gene in our patients was found on genetic analysis.
Nonetheless, the mutation described for the Braunvieh might
be merely a linked marker in that specific breed and not the
causative mutation of SMA (8). Several other enzymes in the
glycosphingolipid pathways are known to be responsible for
neurodegenerative disorders in cattle, and the results in the
Blonde d’Aquitaine could be due to a difference in the level
of linkage disequlibrium between the two breeds, which was
responsible for the loss of the relationship between the marker
and the real causative mutation of SMA in our samples.
In 4–5% of human patients with clinical signs typical of SMA,
no identifiable mutation in the SMN1 gene has been found,
though a number of non-5q causative genes associated with SMA
have been identified to date (21, 22). Other genetic mutations
need to be identified, and naturally occurring animal models
provide an important resource. A mutation screen of the bovine
and the feline SMA gene in a cohort of 96 human patients with
atypical SMA following the identification of genetic mutations
associated with SMA in bovine and feline patients (2, 8, 23) failed
to find mutations in coding sequences or splice sites in human
orthologs, however (24).
Study of the causative gene mutation of SMA in these Blonde
D’Aquitaine calves is currently under way. The identification
of a novel genetic mutation may potentially improve our
understanding of the disease in human medicine.
This is the first report of SMA in Blonde d’Aquitaine calves.
Contrary to previous reports for other bovine breeds, genetic
analysis of the calves and their relatives excluded the involvement
of FVT1 polymorphism in the development of the disease.
Identification of the causative genetic mutation in this breed
could improve our understanding of SMA.
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